A Phase 1/2 interventional study of ONCT-534 in Metastatic Castration-resistant Prostate Cancer, sponsored by Oncternal Therapeutics, Inc. Terminated at 10 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-11.
Sponsored by Oncternal Therapeutics, Inc · Phase 1/2, Interventional, and Treatment
A first-in-human clinical trial to test the investigational treatment ONCT-534 in participants with metastatic castration-resistant prostate cancer. The main questions it aims to answer are:
This is a dose escalation and expansion study where participants will receive daily oral doses of ONCT-534.
This is a Phase 1/2 multi-center study to investigate the safety, tolerability, and anti-tumor acitivity of ONCT-534 in patients with relapsed or refractory metastatic castration-resistant prostate cancer. The study consists of 2 phases: a Phase 1 Dose Escalation and a Phase 2 Dose Expansion.
7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.
This study's enrollment of 21 is below the median of 60 across 5,348 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Oncternal Therapeutics, Inc is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40mg of single agent ONCT-534 to be administered daily in oral tablets
Drug: ONCT-534
80mg of single agent ONCT-534 to be administered daily in oral tablets
Drug: ONCT-534
160mg of single agent ONCT-534 to be administered daily in oral tablets
Drug: ONCT-534
300mg of single agent ONCT-534 to be administered daily in oral tablets
Drug: ONCT-534
600mg of single agent ONCT-534 to be administered daily in oral tablets
Drug: ONCT-534
1200mg of single agent ONCT-534 to be administered daily in oral tablets
Drug: ONCT-534
600mg of single agent ONCT-534 to be administered daily in oral tablets
Drug: ONCT-534
300mg of single agent ONCT-534 to be administered twice daily in oral tablets
Drug: ONCT-534
ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
Also known as: GTx-534, UT-34
Dose Limiting Toxicities Through Study Day 28
Incidence of DLTs through Study Day 28
Time frame: Number of Participants with Dose Limiting Toxicities Through Study Day 28
Reduction of Prostate-Specific Antigen (PSA) by More Than 50%
Proportion of patients who achieve at least a 50% drop in PSA from baseline (PSA50)
Time frame: Up to 51 Weeks
| Milestone | Dose Level 1: 40mg QD | Dose Level 2: 80mg QD | Dose Level 3: 160mg QD | Dose Level 4: 300mg QD | Dose Level 5: 600mg QD | Dose Level 6: 1200 mg QD | BID Dose Level 1: 160 mg BID | BID Dose Level 2: 300 mg BID |
|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 4 | 3 | 3 | 3 | 3 | 3 |
| Safety population | 1 | 1 | 4 | 3 | 3 | 3 | 3 | 3 |
| Dlt-evaluable pop | 1 | 1 | 3 | 3 | 3 | 3 | 3 | 3 |
| Efficacy-evaluable population | 1 | 1 | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 4 | 3 | 3 | 3 | 3 | 3 |
| Withdrew: Progressive disease | 1 | 1 | 2 | 3 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 1 | 0 | 2 | 1 | 3 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Incidence of DLTs through Study Day 28
| Participants | Dose Level 1: 40mg QD | Dose Level 2: 80mg QD | Dose Level 3: 160mg QD | Dose Level 4: 300mg QD | Dose Level 5: 600mg QD | Dose Level 6: 1200 mg QD | BID Dose Level 1: 160 mg BID | BID Dose Level 2: 300 mg BID |
|---|---|---|---|---|---|---|---|---|
| Dose Limiting Toxicities Through Study Day 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Proportion of patients who achieve at least a 50% drop in PSA from baseline (PSA50)
| Participants | Dose Level 1: 40mg QD | Dose Level 2: 80mg QD | Dose Level 3: 160mg QD | Dose Level 4: 300mg QD | Dose Level 5: 600mg QD | Dose Level 6: 1200 mg QD | BID Dose Level 1: 160 mg BID | BID Dose Level 2: 300 mg BID |
|---|---|---|---|---|---|---|---|---|
| Reduction of Prostate-Specific Antigen (PSA) by More Than 50% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Any reduction in PSA after Baseline (First Day of Treatment)
| Participants | Dose Level 1: 40mg QD | Dose Level 2: 80mg QD | Dose Level 3: 160mg QD | Dose Level 4: 300mg QD | Dose Level 5: 600mg QD | Dose Level 6: 1200 mg QD | BID Dose Level 1: 160 mg BID | BID Dose Level 2: 300 mg BID |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Any Post-Baseline Decrease in PSA | 0 | 0 | 2 | 1 | 0 | 2 | 0 | 0 |
Collected over Up to 51 Weeks using the Safety Population. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level 1: 40mg QD | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Dose Level 2: 80mg QD | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Dose Level 3: 160mg QD | 1/4 (25%) | 2/4 (50%) | 4/4 (100%) |
| Dose Level 4: 300mg QD | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Level 5: 600mg QD | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Level 6: 1200 mg QD | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| BID Dose Level 1: 160 mg BID | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| BID Dose Level 2: 300 mg BID | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Dose Level 1: 40mg QD | Dose Level 2: 80mg QD | Dose Level 3: 160mg QD | Dose Level 4: 300mg QD | Dose Level 5: 600mg QD | Dose Level 6: 1200 mg QD | BID Dose Level 1: 160 mg BID | BID Dose Level 2: 300 mg BID |
|---|---|---|---|---|---|---|---|---|
| Back PainMusculoskeletal and connective tissue disorders | 1/1 | 0/1 | 0/4 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 |
| Acute Kidney InjuryRenal and urinary disorders | 0/1 | 0/1 | 1/4 | 1/3 | 0/3 | 1/3 | 0/3 | 0/3 |
| AnaemiaBlood and lymphatic system disorders | 0/1 | 0/1 | 0/4 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 |
| Atypical Haemolytic Uraemic SyndromeBlood and lymphatic system disorders | 0/1 | 0/1 | 0/4 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 |
| Non-cardiac Chest PainGeneral disorders | 0/1 | 0/1 | 0/4 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 |
| Retinal Artery OcclusionEye disorders | 0/1 | 0/1 | 0/4 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 |
| SeromaInjury, poisoning and procedural complications | 0/1 | 0/1 | 0/4 | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| Spinal Cord CompressionNervous system disorders | 0/1 | 0/1 | 0/4 | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| Lactic AcidosisMetabolism and nutrition disorders | 0/1 | 0/1 | 1/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| Urinary Tract ObstructionRenal and urinary disorders | 0/1 | 0/1 | 1/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| Event | Dose Level 1: 40mg QD | Dose Level 2: 80mg QD | Dose Level 3: 160mg QD | Dose Level 4: 300mg QD | Dose Level 5: 600mg QD | Dose Level 6: 1200 mg QD | BID Dose Level 1: 160 mg BID | BID Dose Level 2: 300 mg BID |
|---|---|---|---|---|---|---|---|---|
| Back PainMusculoskeletal and connective tissue disorders | 1/1 | 0/1 | 0/4 | 1/3 | 1/3 | 0/3 | 0/3 | 0/3 |
| FatigueGeneral disorders | 1/1 | 0/1 | 2/4 | 1/3 | 0/3 | 1/3 | 1/3 | 0/3 |
| FlushingVascular disorders | 1/1 | 0/1 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| Hot FlushVascular disorders | 1/1 | 0/1 | 0/4 | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 |
| Lumbroscral PlexopathyNervous system disorders | 1/1 | 0/1 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| ParesthesiaNervous system disorders | 1/1 | 0/1 | 0/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| Oedema PeripheralGeneral disorders | 0/1 | 0/1 | 0/4 | 0/3 | 1/3 | 2/3 | 0/3 | 1/3 |
| Decreased AppetiteMetabolism and nutrition disorders | 0/1 | 0/1 | 2/4 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 |
| NauseaGastrointestinal disorders | 0/1 | 0/1 | 2/4 | 0/3 | 1/3 | 0/3 | 0/3 | 1/3 |
| AnaemiaBlood and lymphatic system disorders | 0/1 | 0/1 | 1/4 | 1/3 | 0/3 | 0/3 | 1/3 | 0/3 |
Safety Population
| Age, Continuous(years) | Dose Level 1: 40mg QD | Dose Level 2: 80mg QD | Dose Level 3: 160mg QD | Dose Level 4: 300mg QD | Dose Level 5: 600mg QD | Dose Level 6: 1200 mg QD | BID Dose Level 1: 160 mg BID | BID Dose Level 2: 300 mg BID | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 53 | 83 | 70.3 ± 3.0 | 67.3 ± 4.5 | 70.0 ± 9.0 | 76.0 ± 5.6 | 67.7 ± 11.7 | 74.0 ± 7.2 | 69.8 ± 8.1 |
| Sex: Female, Male(Participants) | Dose Level 1: 40mg QD | Dose Level 2: 80mg QD | Dose Level 3: 160mg QD | Dose Level 4: 300mg QD | Dose Level 5: 600mg QD | Dose Level 6: 1200 mg QD | BID Dose Level 1: 160 mg BID | BID Dose Level 2: 300 mg BID | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 1 | 1 | 4 | 3 | 3 | 3 | 3 | 3 | 21 |
| Race/Ethnicity, Customized(Participants) | Dose Level 1: 40mg QD | Dose Level 2: 80mg QD | Dose Level 3: 160mg QD | Dose Level 4: 300mg QD | Dose Level 5: 600mg QD | Dose Level 6: 1200 mg QD | BID Dose Level 1: 160 mg BID | BID Dose Level 2: 300 mg BID | Total |
|---|---|---|---|---|---|---|---|---|---|
| White | 1 | 1 | 4 | 2 | 3 | 2 | 2 | 3 | 18 |
| Black or African American | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 3 |
| Region of Enrollment(participants) | Dose Level 1: 40mg QD | Dose Level 2: 80mg QD | Dose Level 3: 160mg QD | Dose Level 4: 300mg QD | Dose Level 5: 600mg QD | Dose Level 6: 1200 mg QD | BID Dose Level 1: 160 mg BID | BID Dose Level 2: 300 mg BID | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 1 | 1 | 4 | 3 | 2 | 2 | 3 | 2 | 18 |
| United Kingdom | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oncternal Therapeutics, Inc